Clinical and prognostic features of Langerhans cell histiocytosis in adults.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Sep 2023
Historique:
revised: 18 04 2023
received: 11 09 2022
accepted: 21 05 2023
medline: 5 9 2023
pubmed: 27 6 2023
entrez: 26 6 2023
Statut: ppublish

Résumé

Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal expansion of CD1a

Identifiants

pubmed: 37364599
doi: 10.1111/cas.15879
pmc: PMC10475785
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3687-3697

Subventions

Organisme : the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
ID : 20FC1018

Informations de copyright

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Lancet Oncol. 2005 Jun;6(6):435-7
pubmed: 15925822
Trends Mol Med. 2020 May;26(5):519-528
pubmed: 32359482
Int J Hematol. 2020 Aug;112(2):185-192
pubmed: 32514929
N Engl J Med. 2002 Feb 14;346(7):484-90
pubmed: 11844849
Cancer Med. 2019 Jan;8(1):58-66
pubmed: 30597769
Am J Surg Pathol. 2018 Feb;42(2):150-159
pubmed: 29194093
Med Pediatr Oncol. 1997 Jan;28(1):9-14
pubmed: 8950330
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Br J Haematol. 2016 Sep;174(6):887-98
pubmed: 27273725
Mol Cancer Ther. 2021 Jul;20(7):1316-1323
pubmed: 33879554
Science. 2017 Mar 24;355(6331):1330-1334
pubmed: 28336671
Blood. 2013 Jun 20;121(25):5006-14
pubmed: 23589673
Ann Oncol. 2010 Jun;21(6):1173-1178
pubmed: 19861578
PLoS One. 2012;7(8):e43257
pubmed: 22916233
Front Med (Lausanne). 2021 Mar 08;7:582581
pubmed: 33763431
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626
Orphanet J Rare Dis. 2013 May 14;8:72
pubmed: 23672541
Cancer. 2006 Aug 1;107(3):613-9
pubmed: 16804933
Int J Hematol. 2013 Jan;97(1):103-8
pubmed: 23243004
Blood. 1999 Jun 15;93(12):4125-30
pubmed: 10361109
J Clin Oncol. 2016 Sep 1;34(25):3023-30
pubmed: 27382093
Pediatr Blood Cancer. 2010 Mar;54(3):416-23
pubmed: 19908293
Leuk Res. 2016 Mar;42:43-6
pubmed: 26859782
Blood. 2008 Mar 1;111(5):2556-62
pubmed: 18089850
Pediatr Blood Cancer. 2006 Feb;46(2):228-33
pubmed: 16047354
J Pediatr. 2001 May;138(5):728-34
pubmed: 11343051
Cancer Sci. 2023 Sep;114(9):3687-3697
pubmed: 37364599
Int J Hematol. 2016 Jul;104(1):99-109
pubmed: 27040279
Hematol Oncol Clin North Am. 2015 Oct;29(5):825-38
pubmed: 26461145
Eur J Cancer. 2003 Nov;39(16):2341-8
pubmed: 14556926
J Clin Invest. 2020 Dec 1;130(12):6668-6676
pubmed: 32897884
Cancer Sci. 2018 Dec;109(12):3707-3713
pubmed: 30281871
Br J Haematol. 2018 Nov;183(4):608-617
pubmed: 30421536
Blood. 2016 Jun 2;127(22):2672-81
pubmed: 26966089
Pediatr Blood Cancer. 2013 Feb;60(2):175-84
pubmed: 23109216
Med Pediatr Oncol. 2002 Dec;39(6):581-5
pubmed: 12376981
Blood Adv. 2023 Feb 28;7(4):664-679
pubmed: 36083130

Auteurs

Aki Sato (A)

Department of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.

Masayuki Kobayashi (M)

Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

Nozomi Yusa (N)

Department of Applied Genomics, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.

Miho Ogawa (M)

Division of Hematopoietic Disease Control, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Eigo Shimizu (E)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Toyotaka Kawamata (T)

Department of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.

Kazuaki Yokoyama (K)

Department of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.

Yasunori Ota (Y)

Department of Diagnostic Pathology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.

Tatsuo Ichinohe (T)

Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Hitoshi Ohno (H)

Department of Hematology, Tenri Hospital, Nara, Japan.

Yasuo Mori (Y)

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Emiko Sakaida (E)

Department of Hematology, Chiba University Hospital, Chiba, Japan.

Tadakazu Kondo (T)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Seiya Imoto (S)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Yasuhito Nannya (Y)

Department of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.
Division of Hematopoietic Disease Control, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Kinuko Mitani (K)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Arinobu Tojo (A)

Institute of Innovation Advancement, Tokyo Medical and Dental University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH